Get the Stockscreener App
3.35
1.82%
0.06
After Hours:
3.34
-0.01
-0.30%
Mereo Biopharma Group Plc Adr stock is traded at $3.35, with a volume of 1.76M.
It is up +1.82% in the last 24 hours and down -6.42% over the past month.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
See More
Previous Close:
$3.29
Open:
$3.28
24h Volume:
1.76M
Relative Volume:
2.29
Market Cap:
$519.74M
Revenue:
$10.00M
Net Income/Loss:
$-29.47M
P/E Ratio:
-11.11
EPS:
-0.3015
Net Cash Flow:
$-21.55M
1W Performance:
-10.43%
1M Performance:
-6.42%
6M Performance:
-13.88%
1Y Performance:
+68.34%
1-Day Range:
$3.11
$3.39
1-Week Range:
$3.11
$3.82
52-Week Range:
$2.02
$5.02
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
Name
Mereo Biopharma Group Plc Adr
Sector
Industry
Phone
4403330237300
Address
ONE CAVENDISH PLACE, LONDON
Compare MREO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
3.35 | 519.74M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | Jefferies | Buy |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-13-23 | Resumed | BTIG Research | Buy |
| Aug-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-05-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Needham | Buy |
View All
Mereo Biopharma Group Plc Adr Stock (MREO) Latest News
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
How Are Things Looking For Mereo Biopharma Group Plc ADR (NASDAQ: MREO) For The Short Term? - Stocks Register
Mereo BioPharma's SWOT analysis: rare disease pipeline drives stock potential - Investing.com
Mereo BioPharma's SWOT analysis: rare disease stock poised for growth - Investing.com
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Do investors need to be concerned about Mereo Biopharma Group Plc ADR (MREO)? - US Post News
Mereo Biopharma Group Plc ADR (MREO) gets rating Initiated from Robert W. Baird - Knox Daily
JP Morgan analysts upgrades an Overweight rating for Nucor Corp. (NUE) - Knox Daily
KeyBanc Capital Markets initates Alignment Healthcare Inc (ALHC) stock to a Sector weight - Knox Daily
Trading Day Review: Mereo Biopharma Group Plc ADR (MREO) Loses Momentum, Closing at 4.16 - The Dwinnex
Natera Inc (NTRA) receives a Buy rating from Jefferies - Knox Daily
Barclays initates Reinsurance Group Of America, Inc. (RGA) stock to an Overweight - Knox Daily
Recent Insider Activity Suggests Potential Gains for Mereo Biopharma Group Plc ADR (MREO) - Knox Daily
Potential Price Increase for Portland General Electric Co (POR) After Recent Insider Activity - Knox Daily
Analysts review KLA Corp.’s rating - Knox Daily
Perhaps timely catching Mereo Biopharma Group Plc ADR (MREO) would be a good idea - SETE News
MREO Stock Sees Surge of Approximately 7.32% in Last Five Days - Knox Daily
Stocks of Mereo Biopharma Group Plc ADR (MREO) are poised to climb above their peers - SETE News
Monitoring Mereo Biopharma Group Plc ADR (MREO) after recent insider movements - Knox Daily
Mereo Biopharma Group Plc ADR (MREO)’s stock price in review: A technical analysis - US Post News
Market Recap Check: Mereo Biopharma Group Plc ADR (MREO)’s Positive Finish at 4.14, Up/Down 0.98 - The Dwinnex
Mereo Biopharma's SWOT analysis: rare disease biotech stock shows promise By Investing.com - Investing.com South Africa
Mereo Biopharma's SWOT analysis: rare disease biotech stock shows promise - Investing.com
Mereo Biopharma Group Plc ADR [NASDAQ: MREO] Sees Increase in Stock Value - Knox Daily
A Look at Mereo Biopharma Group Plc ADR (MREO) Shares in the Recent Past Indicates Growth - SETE News
Examining Mereo Biopharma Group Plc ADR (MREO) more closely is necessary - US Post News
Xylem Inc [XYL] stock was sold by Harker Victoria D at the price of US$0.35 million - Knox Daily
Chief Executive Officer, Scots-Knight Denise sold 60,046 shares of Mereo Biopharma Group Plc ADR [MREO] - Knox Daily
Verona Pharma Plc ADR [VRNA] President and CEO makes an insider sale of 600,000 shares worth $2.25 million. - Knox Daily
MULN’s latest rating updates from top analysts. - Knox Daily
Truist analysts initates a Hold rating for Expedia Group Inc (EXPE) - Knox Daily
Closing Strong: Mereo Biopharma Group Plc ADR (MREO) Ends at 4.09, Down -3.76 from Last Close - The Dwinnex
Investing in Twist Bioscience Corp (TWST): What You Must Know - Knox Daily
Canopy Growth Corporation [CGC] Shares Fall -2.45 % on Wednesday - Knox Daily
Mereo Biopharma Group Plc ADR (MREO) stock: A year of ups and downs - US Post News
Mereo Biopharma Group Plc ADR (MREO) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Mereo BioPharma CFO sells over $120k in company stock - Investing.com India
Mereo BioPharma CFO sells over $121k in company stock - Investing.com
Mereo BioPharma CEO sells over $381k in company stock - Investing.com
Mereo BioPharma's chief scientific officer sells shares worth over $69,000 - Investing.com India
Mereo BioPharma's general counsel sells over $133k in company stock - Investing.com India
Mereo BioPharma executive sells over $637k in company stock - Investing.com
Views of Wall Street’s Leading Experts on Mereo Biopharma Group Plc ADR - SETE News
Market Recap: Mereo Biopharma Group Plc ADR (MREO)’s Negative Momentum, Closing at 4.28 - The Dwinnex
The Potential Rise in the Price of Brixmor Property Group Inc (BRX) following insiders activity - Knox Daily
Taking a Closer Look At Replimune Group Inc (REPL) Following Its Recent Trade - Knox Daily
Mereo Biopharma Group Plc ADR (MREO) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Par Pacific Holdings Inc [PARR] stock for 224,940 USD was sold by Guerra Ivan Daniel - Knox Daily
Evolv Technologies Holdings Inc [EVLV] Shares Rise 1.03 % on Wednesday - Knox Daily
PDCO Shares Experience Surge in Value - Knox Daily
A year in review: Mereo Biopharma Group Plc ADR (MREO)’s performance in the last year - US Post News
Mereo Biopharma Group Plc Adr Stock (MREO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mereo Biopharma Group Plc Adr Stock (MREO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Scots-Knight Denise | Chief Executive Officer |
Sep 12 '24 |
Sale |
4.47 |
28,611 |
127,968 |
868,967 |
| Lewicki John A. | Chief Scientific Officer |
Sep 13 '24 |
Sale |
4.22 |
10,937 |
46,165 |
78,630 |
| Lewicki John A. | Chief Scientific Officer |
Sep 12 '24 |
Sale |
4.47 |
5,212 |
23,312 |
89,567 |
| Sermon Charles | General Counsel |
Sep 13 '24 |
Sale |
4.22 |
20,946 |
88,413 |
219,061 |
| Sermon Charles | General Counsel |
Sep 12 '24 |
Sale |
4.47 |
9,980 |
44,638 |
240,007 |
| Fox Christine Ann | Chief Financial Officer |
Sep 13 '24 |
Sale |
4.22 |
19,158 |
80,866 |
89,285 |
| Fox Christine Ann | Chief Financial Officer |
Sep 12 '24 |
Sale |
4.47 |
9,128 |
40,827 |
108,443 |
| Hughes-Wilson Alexandra | See Remarks |
Sep 13 '24 |
Sale |
4.22 |
100,312 |
423,417 |
50,475 |
| Hughes-Wilson Alexandra | See Remarks |
Sep 12 '24 |
Sale |
4.47 |
47,798 |
213,786 |
150,787 |
| Sermon Charles | General Counsel |
Sep 11 '24 |
Option Exercise |
0.00 |
65,600 |
0 |
249,987 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):